<DOC>
	<DOCNO>NCT02515942</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 12 ( every 28 day ) intravitreal ( IVT ) injection CLG561 monotherapy combination LFG316 compare sham subject geographic atrophy .</brief_summary>
	<brief_title>CLG561 Proof-of-Concept Study Monotherapy Combination With LFG316 Subjects With Geographic Atrophy ( GA )</brief_title>
	<detailed_description>This study consist up-to 30-day screening period , approximately 336-day treatment period , follow-up period consist two visit occur 4 16 week last administered injection .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Sign write informed consent form ; Geographic atrophy eye ; Other protocolspecified inclusion criterion may apply . Pregnant lactate woman woman childbearing potential ; Any medical condition ( systemic ophthalmic ) may preclude safe administration test article safe participation study ; Any contraindication hypersensitivity component LFG316 CLG561 solution ; Any contraindication IVT injection ; Ocular surgery either eye within 90 day screen ; Uncontrolled ocular hypertension glaucoma study eye ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>